SRCM
STLN

Sage Rock Capital Management’s Starling Oncology STLN Stock Holding History

Sage Rock Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-105,691
Closed -$1.05M – 220
2021
Q2 		$1.05M Sell
105,691
-468,109
-82% -$4.71M 0.14% 159
2021
Q1 		$5.71M Sell
573,800
-448,156
-44% -$4.77M 0.69% 50
2020
Q4 		$11M Buy
+1,021,956
New +$10.5M 1.83% 12

Other funds holding STLN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Sage Rock Capital Management's STLN Position: Q3 2021 in Review

Sage Rock Capital Management sold out of Starling Oncology (STLN) in Q3 2021, closing a stake of 105,691 shares — an estimated $1.05M sold.

Sage Rock Capital Management first reported a position in STLN in Q4 2020 and held it in 3 quarters. The position peaked at $11M in Q4 2020. 51 funds tracked by Wall St. Rank hold STLN as of Q3 2021.

  • Sage Rock Capital Management reported no remaining Starling Oncology position as of Q3 2021 after selling out during the quarter.
  • Sage Rock Capital Management sold 105,691 Starling Oncology shares in Q3 2021, an estimated $1.05M.
  • Sage Rock Capital Management first reported a position in Starling Oncology in Q4 2020 and held it in 3 quarters.
  • Sage Rock Capital Management's Starling Oncology position peaked at $11M in Q4 2020.
  • 51 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2021.

Based on Sage Rock Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.